According to the article
According to clinical trials conducted by a group from Kyoto University and other institutions:
- It was confirmed that administering a leukemia drug (Bosutinib) to patients with ALS (Amyotrophic Lateral Sclerosis), a severe disease, showed an effect in slowing the progression of symptoms.
- The trial involved 26 patients who had been diagnosed within the last two years. They were administered the drug over a six-month period, and when compared to a group that did not receive the drug, the effect of slowing the progression of symptoms was confirmed.
- In particular, patients who had relatively low levels of a substance in their blood that indicates nerve damage showed a more pronounced suppression of symptom progression. This suggests the possibility of identifying patients who are likely to benefit most from the drug by examining their blood in advance.
ALS (Amyotrophic Lateral Sclerosis) is a disease where the muscles of the hands, feet, throat, and tongue, as well as those necessary for breathing, gradually weaken and waste away.
The cause is that the nerves responsible for movement are damaged. The brain’s command to “move the body” is not transmitted, resulting in weakened muscles and muscle atrophy.
Blood is produced from hematopoietic stem cells in the bone marrow.
Chronic Myeloid Leukemia is a disease where the hematopoietic stem cells become cancerous, causing the abnormal proliferation of a type of white blood cell called granulocytes. As the disease progresses, normal blood cells cannot be produced, leading to anemia, bleeding, infections, and other life-threatening conditions.
Bosutinib works by inhibiting the function of a protein called “Bcr-Abl tyrosine kinase,” which promotes the proliferation of cancerous leukemia cells. This inhibition suppresses the production of abnormal blood cells, helping to normalize the blood.
Everyone’s Reactions
コメント